HA-Irinotecan Solution for Infusion in Patients with Metastatic Colorectal Cancer

ABSTRACT: Primary objectives: To demonstrate that FOLF(HA)iri is superior to FOLFIRI in prolonging progression free survival (PFS) of irinotecan-naïve patients with metastatic colorectal cancer in the second or third line treatment setting. Primary endpoints: The primary efficacy outcome is PFS based on tumor response assessments established by the independent radiology reviewers

DISEASE(S): Metastatic Colorectal Cancer,Metastatic Colorectal Cancer (mcrc)

PROVIDER: 2528184 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR